Cure My Disease

Don't miss your cure!

 Log in / Sign up

Frailty test could predict who survives liver transplant waiting list

NCT ID NCT03228290

Knowledge-focused Sponsor: University of California, San Francisco Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study follows 5000 adults with advanced liver disease to see how frailty — measured by grip strength, chair stands, and balance — relates to their outcomes before and after a liver transplant. Participants are tested at every clinic visit and for a year after transplant, then followed annually. The goal is to learn whether simple physical tests can help identify who is too frail for transplant or needs extra care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help doctors better predict which liver transplant candidates are too frail for surgery and who might need extra support.
What could go wrong
This is an observational study, not a treatment trial, so it won't directly improve health. Results may not apply to all liver patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 5,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2011

Expected to finish

Dec 2030

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who are being seen for the treatment of their liver disease.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult (≥18 years old) * Are seen for the treatment of liver disease

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End stage liver disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic liver failure End Stage Liver Disease Fibrosis Frailty

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End stage liver disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    8 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Baylor Scott & White Health

    RECRUITING

    Dallas, Texas, 75246, United States

  • Columbia University

    RECRUITING

    New York, New York, 10032, United States

  • Duke University Medical Center

    RECRUITING

    Durham, North Carolina, 27710, United States

  • Indiana University

    ACTIVE_NOT_RECRUITING

    Indianapolis, Indiana, 46202, United States

  • Johns Hopkins

    RECRUITING

    Baltimore, Maryland, 21287, United States

  • Loma Linda University

    COMPLETED

    Loma Linda, California, 92354, United States

  • Northwestern University

    RECRUITING

    Chicago, Illinois, 60611, United States

  • University of Arkansas for Medical Sciences

    COMPLETED

    Little Rock, Arkansas, 72205, United States

  • University of California, San Francisco

    RECRUITING

    San Francisco, California, 94143, United States

  • University of Michigan

    COMPLETED

    Ann Arbor, Michigan, 48109, United States

  • University of Pittsburgh

    RECRUITING

    Pittsburgh, Pennsylvania, 15237, United States

  • University of Washington

    RECRUITING

    Seattle, Washington, 98195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.